Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...
Le Lézard1h
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...